Skip to main content

Metabolic vs Gastroenterology — Deal Terms Comparison

Metabolic Median Upfront
$935M
Total: $4.5B
Gastroenterology Median Upfront
$529M
Total: $2.7B
Metabolic Royalties
16.1%-29.5%
Tiered to 33.5%
Gastroenterology Royalties
7.7%-14.2%
Tiered to 18.2%

Market Analysis

Metabolic and Gastroenterology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 metabolic deals carry a median total deal value of $4.5B with $935M upfront, compared to $2.7B total value and $529M upfront for gastroenterology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do metabolic and gastroenterology deal terms compare?
Metabolic Phase 2 deals average $4.5B total value ($935M upfront), while Gastroenterology deals average $2.7B ($529M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating